With tech from Spinraza's maker, French startup Dynacure gets $55M to tackle neuromuscular disease
Drug discovery powerhouse Ionis gave Biogen one of its biggest wins in recent times with the delivery of Spinraza, the spinal muscular atrophy drug expected to deliver $750 million in sales this year. Since its Spinraza days, Ionis has churned out promising program after promising program, cementing its reputation for delivering clinical assets to its partners.
Now, a collaboration between Ionis and a research institute in France has laid the foundation for a startup that’s tackling another neuromuscular disorder. This time, they’re shooting to develop a drug for centronuclear myopathy, a condition characterized by muscle wasting and muscle weakness. And a group of investors led by Andera Partners (formerly Edmond de Rothschild Investment Partners) has ponied up $55 million to support the research.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.